New Zealand markets closed

Acticor Biotech SAS (ALACT.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
0.5680-0.0020 (-0.35%)
At close: 03:30PM CEST
Full screen
Previous close0.5700
Open0.5820
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.5680 - 0.5820
52-week range0.2700 - 6.0000
Volume2,931
Avg. volume120,878
Market cap8.81M
Beta (5Y monthly)0.26
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

    PARIS, July 18, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

  • Business Wire

    Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2024

    PARIS, July 17, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of June 30, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

  • Business Wire

    Acticor Biotech publishes its 2023 annual results

    PARIS, July 09, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today publishes its 2023 annual results, for the year ending December 31, 2023, approved by the Board of Directors on July 9, 2024.